Wound treatment-dressing and method of manufacture
AssigneeHarvey E. Svetlik
InventorHarvey E. Svetlik
Life of this patent
Estimating the term…
Abstract
A wound treatment-dressing is shown which includes a dressing body formed from a medically inert, moisture permeable, urethane open-cell foam which is hydrophilic in nature. The foam body has a foam matrix of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobials as active agents, the active agents being incorporated into the foam matrix both topically on a foam cell surface and integrally within the foam cell wall. The antimicrobials are manufactured in a selected particle size range which improves predictability and performance of the wound dressing.
Claims8
A wound treatment-dressing, comprising:
- a dressing body having at least a wound contacting surface layer which is formed from a hydrophilic, capillary active, medically inert, moisture permeable, urethane open-cell foam which provides conformational area contact over the wound treatment area without local non-contact;
- wherein the foam which makes up at least the wound contacting surface of the dressing body exists as a foam matrix comprised of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobial particles as active agents, the active agents being incorporated into the foam matrix both protruding through the foam cell wall and integrally within the foam cell wall, whereby the foam functions by capillary and hydrophilic action as a liquid absorber with liquid exudate being absorbed from the wound treatment area into the foam matrix where it is retained against free flow out of the wound treatment-dressing and is kept away from the wound to facilitate healing, whereby microbial organisms are removed from the wound and killed in an external killing zone;
- wherein the particles which are encapsulated into the foam matrix consist of gentian-violet, methylene-blue and colloidal or ionic silver, wherein the gentian-violet and methylene-blue components are present in the foam matrix as nano-sized particles which range in spherical diameter from about 19 microns to 8000 microns, and wherein the dressing body having the previously described characteristics comprises a finished manufactured foam wound treatment-dressing which has an antimicrobial concentration of each of the gentian-violet, methylene-blue and colloidal or ionic silver components in the range from 0.0001% to 9% (gr/gr) by weight of each component;
- and
- wherein the dressing body which makes up the finished manufactured foam wound treatment-dressing has a thickness in the range from about 2 to 10 mm.
a wound treatment comprising:
- a dressing body having at least a wound contacting surface layer which is formed from a hydrophilic, capillary active, medically inert, moisture permeable, urethane open-cell foam which provides conformational area contact over the wound treatment area without local non-contact;
- wherein the foam which makes up at least the wound contacting surface of the dressing body exists as a foam matrix comprised of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobial particles as active agents, the active agents being incorporated into the mechanically active foam matrix both protruding from the foam cell surface and integrally within the foam cell wall, whereby the foam functions as a liquid absorber with liquid exudate being absorbed from the wound treatment area into the foam matrix where it is retained against free flow out of the wound treatment-dressing and is kept away from the wound to facilitate healing, whereby microbial organisms are removed from the wound and killed in an external killing zone;
- wherein the open-cell foam is made by the steps of:
- physically mixing a given weight percentage of each antimicrobial agent, in the form of particles, into a solution of polymer foam ingredients prior to foaming;
- and
- producing a finished manufactured foam wound treatment-dressing from the polymer foam ingredients, including the antimicrobial agents, in a foaming step such that the antimicrobials are mechanically included in the foam cell wall upon foaming, whereby some quantity of antimicrobial particles will be totally encapsulated into the wall's interconnected foam cells with a remaining quantity protruding through the foam cell walls to be physically exposed into the void space of present in the open-foam cell, the incorporation of the antimicrobial particles during the foaming step resulting in the antimicrobial particles being physically captured and no longer mobile;
- wherein the particles which are encapsulated into the foam matrix of consist [essentially] of gentian-violet, methylene-blue and colloidal or ionic silver, wherein the gentian-violet and methylene-blue components are present in the foam matrix as nano-sized particles which range in spherical diameter from about 19 microns to 8000 microns, manufactured foam wound treatment-dressing which has an antimicrobial concentration of each of the gentian-violet, methylene-blue and colloidal or ionic silver components in the range from 0.0001% to 9% (gr/gr) by weight of each component;
- and
- wherein the foam dressing body which makes up the finished manufactured foam wound treatment-dressing has a thickness in the range from about 2 to 10 mm.
Dependencies are inferred from the claim text.